Literature DB >> 3144216

Severe acute respiratory failure managed with continuous positive airway pressure and partial extracorporeal carbon dioxide removal by an artificial membrane lung. A controlled, randomized animal study.

M Borelli1, T Kolobow, R Spatola, P Prato, K Tsuno.   

Abstract

Using an animal model of acute respiratory failure (ARF), we evaluated two treatments: conventional mechanical pulmonary ventilation (MV) and continuous positive airway pressure (CPAP) with extracorporeal removal of CO2 by an artificial membrane lung. We developed a model of "mild" ARF and a model of "severe" ARF after ventilating healthy sheep at a peak inspiratory pressure of 50 cm H2O for various lengths of time. Sheep from either injury models were randomly assigned to one of the above treatment groups. All 16 sheep from the model with "severe" ARF died, with progressive deterioration in pulmonary function and multiorgan failure irrespective of the treatment. Of 11 sheep from the model with "mild" ARF treated by MV, only three survived, whereas all 11 sheep from the model with "mild" ARF treated with CPAP and extracorporeal removal of CO2 responded well, and nine sheep ultimately recovered. We conclude that CPAP with extracorporeal removal of CO2 provided a better environment for the recovery in our model with "mild" ARF than the conventional arrangement centered on MV alone. Our studies also suggest that lung injury can progress (i.e., model with "severe" ARF) to where neither of the two treatments can succeed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144216     DOI: 10.1164/ajrccm/138.6.1480

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

1.  Target blood gases during ARDS ventilatory management.

Authors:  A Pesenti
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  Barotrauma is volutrauma, but which volume is the one responsible?

Authors:  D Dreyfuss; G Saumon
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

3.  A nordic ECMO saga or whither ECMO?

Authors:  W M Zapol
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  Reduced ventilator pressure and improved P/F ratio during percutaneous arteriovenous carbon dioxide removal for severe respiratory failure.

Authors:  S K Alpard; J B Zwischenberger; W Tao; D J Deyo; A Bidani
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

Review 5.  Ventilatory management of ARDS: can it affect the outcome?

Authors:  K G Hickling
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

6.  From ventilator-induced lung injury to multiple organ dysfunction?

Authors:  D Dreyfuss; G Saumon
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

Review 7.  Is ventilator-induced lung injury a promoter of multiple organ failure in adult respiratory distress syndrome? The effect of permissive hypercapnia on oxygenation and outcome.

Authors:  Keith G Hickling
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

8.  Arteriovenous CO2 removal improves survival compared to high frequency percussive and low tidal volume ventilation in a smoke/burn sheep acute respiratory distress syndrome model.

Authors:  Frank C Schmalstieg; Susan E Keeney; Helen E Rudloff; Kimberly H Palkowetz; Manuel Cevallos; Xiaoquin Zhou; Robert A Cox; Hal K Hawkins; Daniel L Traber; Joseph B Zwischenberger
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

9.  Aging increases the susceptibility to injurious mechanical ventilation.

Authors:  Nicolás Nin; José A Lorente; Marta De Paula; Pilar Fernández-Segoviano; Oscar Peñuelas; Alberto Sánchez-Ferrer; Leticia Martínez-Caro; Andrés Esteban
Journal:  Intensive Care Med       Date:  2008-01-05       Impact factor: 17.440

10.  Rats surviving injurious mechanical ventilation show reversible pulmonary, vascular and inflammatory changes.

Authors:  Nicolás Nin; José A Lorente; Marta de Paula; Mariam El Assar; Susana Vallejo; Oscar Peñuelas; Pilar Fernández-Segoviano; Antonio Ferruelo; Alberto Sánchez-Ferrer; Andrés Esteban
Journal:  Intensive Care Med       Date:  2008-01-05       Impact factor: 17.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.